Facility-level changes in receipt of pharmacotherapy for opioid use disorder: Implications for implementation science

Facility-level changes in receipt of pharmacotherapy for opioid use disorder: Implications for implementation science

Background: The U.S. is facing an opioid epidemic, but despite mandates for pharmacotherapy for opioid use disorder to be available at Veterans Health Administration (VHA) facilities, the majority of veterans with opioid use disorder do not receive these medications. In implementation research, faci...

Full description

Bibliographic Details
Main Authors: Binswanger, I.A (Author), Bowe, T. (Author), Finlay, A.K (Author), Harris, A.H.S (Author), Smelson, D. (Author), Stimmel, M.A (Author), Timko, C. (Author), Yu, M. (Author)
Format: Article
Language:English
Published: Elsevier Inc. 2018
Subjects:
Article
buprenorphine
Buprenorphine
clinical trial
drug therapy
government
health care quality
health care system
health care utilization
Hospitals, Veterans
human
Humans
Implementation science
Implementation Science
methadone
Methadone
multicenter study
naltrexone
Naltrexone
opiate addiction
opiate substitution treatment
Opiate Substitution Treatment
Opioid-related disorders
Opioid-Related Disorders
Pharmacotherapy
priority journal
procedures
public hospital
Quality Improvement
Quality Indicators, Health Care
total quality management
United States
United States Department of Veterans Affairs
veteran
Veterans
veterans health
Online Access:View Fulltext in Publisher

Internet

View Fulltext in Publisher

Similar Items